TABLE 2.
Sensitivity, specificity, and agreement of the PANDAA assay versus Sanger sequencinga
| Mutation | TP | TN | FP | FN | % Sensitivity (95% CI) | % Specificity (95% CI) | Kappa value (95% CI) |
|---|---|---|---|---|---|---|---|
| K65R | 38 | 109 | 1 | 2 | 95 (83–99) | 99 (95–100) | 0.95 (0.89–1.00) |
| M184V/I | 80 | 69 | 0 | 1 | 99 (93–100) | 100 (95–100) | 0.99 (0.96–1.01) |
| NRTI DRMs | 87 | 61 | 0 | 2 | 98 (92–100) | 100 (94–100) | 0.90 (0.83–0.97) |
| K103NS | 54 | 93 | 2 | 1 | 98 (90–100) | 98 (93–100) | 0.96 (0.91–1.01) |
| Y181C | 41 | 90 | 18 | 1 | 98 (87–100) | 83 (75–90) | 0.72 (0.60–0.84) |
| G190A | 47 | 93 | 9 | 1 | 98 (89–100) | 91 (84–96) | 0.85 (0.77–0.94) |
| NNRTI DRMs | 105 | 34 | 11 | 0 | 100 (97–100) | 76 (61–87) | 0.85 (0.75–0.95) |
a
TP, true positive; TN, true negative; FP, false positive; FN, false negative; CI, confidence interval; NRTI DRMs, mutations resulting in resistance to nucleotide reverse transcriptase inhibitors; NNRTI DRMs, mutations resulting in resistance to non-NRTIs. The row “NRTI DRMs” presents the frequency of NRTI mutations detected either individually or together (K65R and/or M184V). Similarly, the row “NNRTI DRMs” presents the frequency of NNRTI mutations detected either individually or together (K103N and/or Y181C and/or G190A).